Journal
FRONTIERS IN PHYSIOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphys.2022.844042
Keywords
stress erythropoiesis; erythroid progenitors; anemia; cancer; erythropoietin
Categories
Funding
- Ministry of Education, Science, and Technological Development of the Republic of Serbia [451-03-9/2021-14/200015, 451-03-68/2022-14/200015]
Ask authors/readers for more resources
Cancer-related anemia (CRA) is a common disorder that negatively affects the quality of life and prognosis in cancer patients. Stress erythropoiesis (SE) plays a pivotal role in CRA, but chronic SE may lead to ineffective erythropoiesis, worsening the condition. Therefore, there is an urgent need to control ineffective erythropoiesis in cancer patients and develop personalized treatment strategies for CRA management.
Cancer-related anemia (CRA) is a common multifactorial disorder that adversely affects the quality of life and overall prognosis in patients with cancer. Safety concerns associated with the most common CRA treatment options, including intravenous iron therapy and erythropoietic-stimulating agents, have often resulted in no or suboptimal anemia management for many cancer patients. Chronic anemia creates a vital need to restore normal erythropoietic output and therefore activates the mechanisms of stress erythropoiesis (SE). A growing body of evidence demonstrates that bone morphogenetic protein 4 (BMP4) signaling, along with glucocorticoids, erythropoietin, stem cell factor, growth differentiation factor 15 (GDF15) and hypoxia-inducible factors, plays a pivotal role in SE. Nevertheless, a chronic state of SE may lead to ineffective erythropoiesis, characterized by the expansion of erythroid progenitor pool, that largely fails to differentiate and give rise to mature red blood cells, further aggravating CRA. In this review, we summarize the current state of knowledge on the emerging roles for stress erythroid progenitors and activated SE pathways in tumor progression, highlighting the urgent need to suppress ineffective erythropoiesis in cancer patients and develop an optimal treatment strategy as well as a personalized approach to CRA management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available